Head-To-Head Review: Pulmonx (NASDAQ:LUNG) vs. LivaNova (NASDAQ:LIVN)

LivaNova (NASDAQ:LIVN – Get Free Report) and Pulmonx (NASDAQ:LUNG – Get Free Report) are both healthcare companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, risk, profitability, valuation, dividends and earnings.

Earnings and Valuation

This table compares LivaNova and Pulmonx”s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
LivaNova $1.39 billion 3.67 -$242.47 million $3.00 30.81
Pulmonx $88.78 million 1.37 -$54.00 million ($1.01) -2.77

Pulmonx has lower revenue, but higher earnings than LivaNova. Pulmonx is trading at a lower price-to-earnings ratio than LivaNova, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

97.6% of LivaNova shares are owned by institutional investors. Comparatively, 91.0% of Pulmonx shares are owned by institutional investors. 0.3% of LivaNova shares are owned by company insiders. Comparatively, 7.5% of Pulmonx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Analyst Recommendations

This is a summary of current ratings and recommmendations for LivaNova and Pulmonx, as provided by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
LivaNova 0 3 9 0 2.75
Pulmonx 1 0 3 0 2.50

LivaNova presently has a consensus target price of $101.22, suggesting a potential upside of 9.50%. Pulmonx has a consensus target price of $7.67, suggesting a potential upside of 173.81%. Given Pulmonx’s higher possible upside, analysts plainly believe Pulmonx is more favorable than LivaNova.

Volatility and Risk

LivaNova has a beta of 0.91, indicating that its stock price is 9% less volatile than the S&P 500. Comparatively, Pulmonx has a beta of 0.19, indicating that its stock price is 81% less volatile than the S&P 500.

Profitability

This table compares LivaNova and Pulmonx’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
LivaNova 13.01% 16.10% 7.85%
Pulmonx -47.93% -98.23% -35.89%

Summary

LivaNova beats Pulmonx on 11 of the 14 factors compared between the two stocks.

About LivaNova

(Get Free Report)

LivaNova plc is a global medical technology company that develops and manufactures products for cardiovascular care and neuromodulation. The company was formed in 2015 through the combination of Cyberonics and Sorin Group. In neuromodulation, LivaNova’s VNS Therapy system delivers vagus nerve stimulation and is used as an adjunctive treatment for certain people with drug-resistant epilepsy and treatment-resistant depression. Its cardiovascular products support cardiac surgery and include heart-lung machines, oxygenators and related perfusion equipment.

About Pulmonx

(Get Free Report)

Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company’s Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.